Neurocrine Biosciences Commences Phase 1 Trial to Assess the Impact of New VMAT2 Blocker NBI-1065890 on Healthy Adults

Neurocrine Biosciences, a biopharmaceutical company specializing in neuroscience, has launched a Phase 1 clinical trial for NBI-1065890, an experimental oral medication. This compound is a selective inhibitor of vesicular monoamine transporter-2 (VMAT2), which is being investigated for its potential to treat specific neurological and neuropsychiatric disorders. The study aims to assess the compound's safety, tolerability, pharmacokinetics, and pharmacodynamics in a group of healthy adults.
The company has a strong background in VMAT2 inhibition, as demonstrated by its development of valbenazine, a drug used to treat tardive dyskinesia and chorea associated with Huntington's disease. Valbenazine was the first of its kind for treating tardive dyskinesia and received FDA approval in 2017. More recently, in 2023, the drug was also approved for the treatment of chorea related to Huntington's disease.
Eiry W. Roberts, M.D., Neurocrine's Chief Medical Officer, expressed enthusiasm about the new VMAT2 inhibitor, noting the company's expertise in this area and the hope that NBI-1065890 will offer significant benefits for patients with neurological and neuropsychiatric conditions. VMAT2 inhibitors have proven effective in treating hyperkinetic movement disorders due to their role in regulating dopamine storage and release at the presynaptic level.
Neurocrine Biosciences is committed to creating transformative treatments for patients suffering from neurological, neuroendocrine, and neuropsychiatric disorders that are often underserved by current medical options. Their portfolio encompasses a range of FDA-approved treatments and a pipeline of promising compounds in various stages of clinical development. With three decades of experience, the company leverages its deep understanding of neuroscience to address complex medical challenges, striving to alleviate the burden of severe diseases and disorders through innovative medicines.
The company's mission is encapsulated in its tagline, "You Deserve Brave Science," reflecting its dedication to bold and pioneering research. Neurocrine's efforts are aimed at improving the lives of those facing debilitating conditions, and they continue to explore new avenues in neuroscience to achieve this goal. The development of NBI-1065890 represents the latest chapter in their pursuit of innovative treatments for neurological conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!